Compare OSCR & AMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OSCR | AMRX |
|---|---|---|
| Founded | 2012 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Accident &Health Insurance | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 3.7B |
| IPO Year | 2021 | 2018 |
| Metric | OSCR | AMRX |
|---|---|---|
| Price | $17.94 | $12.78 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 5 |
| Target Price | ★ $16.88 | $15.60 |
| AVG Volume (30 Days) | ★ 5.5M | 1.4M |
| Earning Date | 05-06-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 157.89 |
| EPS | N/A | ★ 0.22 |
| Revenue | ★ $11,701,427,000.00 | N/A |
| Revenue This Year | $63.89 | $4.48 |
| Revenue Next Year | $5.30 | $7.13 |
| P/E Ratio | ★ N/A | $57.57 |
| Revenue Growth | ★ 27.50 | N/A |
| 52 Week Low | $10.69 | $7.02 |
| 52 Week High | $23.80 | $15.42 |
| Indicator | OSCR | AMRX |
|---|---|---|
| Relative Strength Index (RSI) | 75.98 | 49.87 |
| Support Level | $17.37 | $12.50 |
| Resistance Level | $18.86 | $12.85 |
| Average True Range (ATR) | 0.74 | 0.49 |
| MACD | 0.27 | -0.01 |
| Stochastic Oscillator | 95.99 | 30.56 |
Oscar Health Inc is a healthcare technology company built around a full stack technology platform and a relentless focus on serving its members. It offers Individual & Family plans and health technology solutions that power the healthcare industry. Oscar operates as one segment to sell insurance to individuals, families and employees through the federal and state-run healthcare exchanges formed in conjunction with the Patient Protection and Affordable Care Act (ACA) and leverages its technology platform to provide services via its Oscar offering.
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE. It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment, which derives maximum revenue, focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.